Prolonged critical illness produces dynamic and often unpredictable alterations in drug pharmacokinetics. Changes in cardiac output, regional blood flow, capillary permeability, plasma protein concentrations, renal function, hepatic metabolism, and extracorporeal support can substantially modify drug absorption, distribution, metabolism, and elimination. These processes may evolve over hours or days, creating a moving pharmacokinetic target that differs from the profile observed at intensive care unit admission. Early critical illness is commonly characterized by increased extracellular volume, augmented cardiac output, systemic inflammation, and capillary leak, whereas later phases may involve persistent organ dysfunction, malnutrition, tissue edema, altered drug-binding proteins, and variable clearance. The resulting exposure may be inadequate for antimicrobials, sedatives, analgesics, antiepileptic drugs, and other time-sensitive therapies, while accumulation and toxicity may occur when clearance declines or extracorporeal circuits remove active drug. Optimal management requires mechanism-based dose selection, frequent reassessment, therapeutic drug monitoring when available, and integration of clinical, laboratory, and organ-support data. This review summarizes the principal pharmacokinetic changes during prolonged critical illness and their implications for diagnosis, treatment, guideline-based prescribing, and emerging precision dosing strategies.
Critical illness is not a static physiological state. Drug disposition changes as sepsis, shock, inflammation, surgery, burns, trauma, organ failure, nutritional impairment, and intensive care interventions evolve. A standard dose derived from healthy volunteers or stable ward patients may therefore produce substantially different exposure in a mechanically ventilated or extracorporeally supported patient. The conventional pharmacokinetic processes of absorption, distribution, metabolism, and excretion are each affected, and the magnitude and direction of change may differ between patients and across time.
Prolonged intensive care is particularly challenging because initial hyperdynamic physiology may be followed by vasopressor dependence, acute kidney injury, hepatic dysfunction, fluid accumulation, muscle wasting, and altered immune responses. Drug concentrations can consequently change despite an unchanged prescription. The clinical consequences include treatment failure, resistance selection, withdrawal syndromes, excessive sedation, neurotoxicity, bleeding, and avoidable adverse drug reactions. A clinically useful approach must regard pharmacokinetic assessment as a continuous process rather than a single calculation performed at admission.
Medication-related problems are common in critically ill populations, particularly among patients with sepsis, multiorgan failure, prolonged mechanical ventilation, and prolonged exposure to antimicrobials or sedative infusions. Subtherapeutic antimicrobial concentrations have been reported in patients receiving beta-lactams, glycopeptides, aminoglycosides, and antifungal agents, while excessive exposure is also frequent when renal function deteriorates or dosing is not adjusted during changing organ support. The burden extends beyond infection. Altered clearance of opioids, benzodiazepines, antiepileptic drugs, anticoagulants, and immunosuppressants can prolong ventilation, delay neurological assessment, and increase bleeding or toxicity.
Population-level estimates vary because studies use different definitions of pharmacokinetic target attainment and include heterogeneous intensive care cohorts. Nevertheless, the consistent finding is clinically important interpatient variability. Standard renal and hepatic laboratory values may not accurately represent drug clearance, especially in patients with low muscle mass, severe edema, rapidly changing physiology, or extracorporeal therapies. This variability supports individualized dosing and repeated reassessment in prolonged critical illness.
Systemic inflammation increases endothelial permeability and disrupts the glycocalyx, allowing plasma water and proteins to move into the interstitial space. Intravenous fluid administration further expands total body water and extracellular volume. Hydrophilic drugs therefore often have a larger volume of distribution, leading to lower initial plasma concentrations after conventional loading doses. Edema, ascites, pleural effusions, and third spacing can also create tissue reservoirs that delay equilibration and prolong terminal disposition.
Hypoalbuminemia and reduced concentrations of alpha-1-acid glycoprotein alter protein binding. Highly albumin-bound acidic drugs may have a greater unbound fraction, while basic drugs may behave differently as acute-phase proteins increase. Since pharmacological activity and clearance frequently depend on unbound drug, total plasma concentrations can be misleading. A total concentration within a conventional therapeutic range may coexist with excessive active exposure, or a low total concentration may conceal an adequate unbound concentration.
Cardiac output and regional perfusion influence delivery to the liver, kidneys, and other organs. In the hyperdynamic phase of sepsis, augmented renal clearance may produce unexpectedly rapid elimination of renally cleared drugs. Conversely, shock, vasoconstriction, intra-abdominal hypertension, and renal hypoperfusion may reduce clearance. Hepatic metabolism can be impaired by reduced blood flow, cellular dysfunction, cholestasis, inflammation-mediated enzyme suppression, and drug interactions. Critical illness may also alter transporter activity and intestinal function, making oral absorption unreliable.
Renal replacement therapy introduces additional complexity. Intermittent hemodialysis, continuous kidney replacement therapy, and prolonged intermittent therapies differ in clearance according to effluent flow, membrane characteristics, filter age, protein binding, molecular size, and treatment interruptions. Extracorporeal membrane oxygenation may sequester lipophilic or highly protein-bound drugs within the circuit and increase apparent distribution volume. These effects can change over time as the circuit matures and as patient physiology changes.
Major risk factors include septic shock, severe burns, trauma, pancreatitis, extensive surgery, persistent capillary leak, large-volume crystalloid resuscitation, obesity, very low body weight, hypoalbuminemia, augmented renal clearance, acute kidney injury, chronic liver disease, cholestasis, malnutrition, prolonged immobilization, and multiple organ dysfunction. Mechanical ventilation, vasopressor therapy, extracorporeal support, continuous renal replacement therapy, and frequent interruptions of nutrition or enteral administration further increase uncertainty.
Polypharmacy is an additional determinant of risk. Enzyme inducers and inhibitors, acid-suppressive drugs, anticonvulsants, immunosuppressants, and antimicrobial combinations can produce clinically meaningful interactions. Genetic variation in metabolic enzymes may contribute, but the effects of critical illness, inflammation, organ support, and rapidly changing physiology often exceed the influence of genotype alone during the acute phase.
Pharmacokinetic disturbance does not have a unique clinical presentation. Treatment failure may appear as persistent fever, bacteremia, delayed microbiological clearance, recurrent seizures, inadequate analgesia, or agitation despite apparently appropriate therapy. Excess exposure may manifest as oversedation, delayed awakening, respiratory depression, delirium, hypotension, nephrotoxicity, hepatotoxicity, ototoxicity, bleeding, or prolonged neuromuscular weakness. Accumulation is especially likely when infusions continue during declining renal or hepatic function.
Clinical interpretation is complicated by overlapping manifestations of critical illness. Delirium may reflect infection, withdrawal, metabolic disturbance, or sedative accumulation. Hypotension may result from sepsis, vasodilation, or excessive drug effect. Neurological examination, urine output, fluid balance, hemodynamic trends, and the timing of drug administration should therefore be reviewed together rather than interpreted in isolation.
Assessment begins with a complete medication and organ-support history. Clinicians should document indication, dose, route, infusion duration, loading strategy, timing of administration, nutrition status, renal replacement settings, extracorporeal circuits, and recent changes in kidney and liver function. Serum creatinine alone may lag behind abrupt changes in filtration and may overestimate renal function in patients with sarcopenia. Urine output, measured creatinine clearance when feasible, fluid balance, and trends in renal biomarkers can provide complementary information.
Therapeutic drug monitoring is valuable for medicines with narrow therapeutic indices or established exposure targets. Concentration interpretation should account for sampling time, distribution phase, dosing history, albumin concentration, and whether the assay measures total or unbound drug. Bayesian forecasting and population pharmacokinetic models can integrate sparse concentrations with patient-specific covariates. For beta-lactams, prolonged or continuous infusion with concentration assessment may improve target attainment, although local laboratory capacity and validated targets are required.
Loading doses should generally be based on the anticipated volume of distribution rather than on maintenance clearance alone. Hydrophilic antimicrobials may require larger initial doses in patients with marked fluid expansion, while the maintenance regimen should be adjusted as renal and hepatic function evolve. Lipophilic drugs may have extensive tissue distribution and delayed recovery from accumulation, making repeated boluses and prolonged infusions particularly important to reassess.
Maintenance dosing should be individualized according to the desired pharmacodynamic target. Time-dependent antimicrobials are commonly managed by maximizing the percentage of the dosing interval during which free concentrations exceed the pathogen-specific minimum inhibitory concentration. Concentration-dependent agents require attention to peak exposure, whereas exposure-dependent medicines are guided by an area-under-the-curve target. Dose adjustment should reflect measured or estimated clearance, not merely the presence of a diagnostic label such as acute kidney injury.
Medication review should occur whenever there is a change in vasopressor requirement, fluid balance, urine output, liver tests, renal replacement settings, nutritional route, or level of consciousness. Sedatives and analgesics should be titrated to validated clinical targets, with daily evaluation of accumulation and opportunities for lighter sedation. Drug interactions should be actively screened, and enteral administration should be avoided or modified when gastrointestinal absorption is unreliable. Pharmacists, intensivists, infectious disease specialists, nurses, and clinical pharmacologists should collaborate on high-risk regimens.
Precision dosing is increasingly supported by Bayesian software, real-time concentration measurement, and physiologically based pharmacokinetic models. These tools can estimate individual clearance and volume of distribution from limited samples and may be particularly useful when conventional equations are unreliable. Continuous or near-continuous antimicrobial assays could permit earlier dose correction in severe infection, although implementation requires validated methods, quality assurance, and integration with antimicrobial stewardship.
Research is also examining inflammation-informed pharmacology, unbound drug monitoring, novel biomarkers of kidney function, and model-informed dosing during extracorporeal support. Machine-learning systems may identify patients at risk for augmented renal clearance or drug accumulation, but their clinical value depends on external validation, interpretability, and prospective demonstration of improved outcomes. Emerging therapies should complement rather than replace bedside assessment and established pharmacodynamic principles.
Contemporary critical care and infectious disease guidance generally supports an initial adequate loading dose for severe infection, prompt administration of effective antimicrobial therapy, and subsequent individualized adjustment based on organ function, pharmacodynamic targets, and therapeutic drug monitoring where appropriate. Extended or continuous infusion is recommended or considered for selected time-dependent antibiotics when compatible with the drug, stability requirements, and local protocols. Renal replacement prescriptions and antimicrobial regimens should be reviewed together because changes in effluent rate can alter clearance.
Guideline implementation should include structured medication reconciliation, daily assessment of dose appropriateness, documentation of therapeutic targets, evaluation of drug interactions, and multidisciplinary review of medicines with narrow safety margins. Local antibiograms, laboratory capabilities, resistance patterns, and validated institutional protocols should guide specific targets. No guideline can fully substitute for reassessment because the pharmacokinetic state of a prolonged intensive care patient may change faster than scheduled monitoring intervals.
Prolonged critical illness transforms drug disposition through interacting changes in fluid distribution, protein binding, tissue perfusion, metabolism, renal clearance, gastrointestinal function, and extracorporeal removal. These mechanisms produce substantial variability and may shift rapidly from augmented clearance to drug accumulation. Safe and effective prescribing therefore requires an integrated, time-sensitive strategy that combines appropriate loading, mechanism-based maintenance dosing, pharmacodynamic target selection, therapeutic drug monitoring, and repeated review of organ function and life-support therapies. Precision dosing technologies and improved biomarkers may strengthen this approach, but careful clinical observation and multidisciplinary decision-making remain fundamental to achieving therapeutic exposure while limiting toxicity.
1.
A small rise in cancer was observed following the 1986 Chernobyl accident.
2.
CAR-T Induces Deep, Durable Remission in Smoldering Myeloma
3.
Prostate cancer, rectal exams, Casgevy approved for thalassemia, and two million cancer cases.
4.
Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial
5.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
1.
Developmental Regulation of Pediatric Red-Cell Production
2.
Exploring the Benefits of Flexible Sigmoidoscopy: A Revolutionary Way to Detect Colorectal Cancer
3.
Robotic Intratumoral Resection for Organ Preservation: Current Evidence and Clinical Implications
4.
Clinical Analysis of Prostate Cancer
5.
Leptomeningeal Carcinomatosis: Symptoms, Causes, and Treatment Options
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Signs and Symptoms of Leukemia
2.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
3.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
5.
The Role of Hemoglobin in Maintaining Healthy Oxygen Levels
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation